Patrick Royston

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial

M. Parmar, M. Sydes, D. Dearnaley, 2009, Trials.

How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design – a reanalysis of 4 trials

P. Royston, F. M. Barthel, FM-S Barthel, 2009, Trials.

Evaluation of sample size and power for multi‐arm survival trials allowing for non‐uniform accrual, non‐proportional hazards, loss to follow‐up and cross‐over

P Royston, P. Royston, P. Royston, 2006, Statistics in medicine.

Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols

M. Parmar, M. Sydes, P. Royston, 2017, Clinical trials.

Response: Re: Visualizing Length of Survival in Time-to-Event Studies: A Complement to Kaplan–Meier Plots

P. Royston, M. Parmar, D. Altman, 2008 .

artbin: Extended sample size for randomized trials with binary outcomes

Ian R. White, P. Royston, A. Babiker, 2023, The Stata journal.

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer

E. Frangou, M. Stockler, M. Parmar, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A simulation study of predictive ability measures in a survival model II: explained randomness and predictive accuracy

P Royston, Mahesh K B Parmar, P. Royston, 2012, Statistics in medicine.

Speeding up the Evaluation of New Agents in Cancer

M. Parmar, M. Sydes, E. Eisenhauer, 2008, Journal of the National Cancer Institute.